https://orcid.org/0000-0001-6311-5428
Figures
Abstract
Background
Tuberculosis (TB) is one of the most common opportunistic infections in people living with HIV (PLHIV). Mycobacterium tuberculosis may cause more TB in all stages of HIV infection than in the general population, with the incidence of TB and the spread of pulmonary TB to other organs increasing as the CD4 count decreases.
Objective
In this HIV cohort study, we aimed to evaluate the clinical features, diagnosis, and prognosis of TB among PLHIV in Türkiye.
Materials and methods
We conducted a retrospective cohort study to analyze clinical outcomes and identify determinants of mortality among people living with HIV (PLHIV) co-infected with tuberculosis. We included 264 patients diagnosed and treated for TB across six centers in Türkiye. We extracted clinical, demographic, laboratory, microbiological, and radiological data from patient medical records. To identify independent predictors of mortality, we performed multivariable logistic regression and reported the results as odds ratios (ORs) with 95% confidence intervals (CIs).
Results
Of the 9,687 PLHIV who were followed for 10 years, 2.7% (264 individuals) developed TB. The median age of these individuals was 40 years, and 89% were male.
The prevalence of pulmonary TB only, extrapulmonary TB only, and the coexistence of pulmonary and extrapulmonary TB were 42.4%, 48.8%, and 8.7%, respectively. Opportunistic infections and cancers were found in 23% (62 out of 264) of patients with HIV/TB co-infection. Among patients with HIV/TB co-infection, 42% showed lymphadenopathy, with 70% of these cases being generalized. In patients who underwent chest CT scans (n=200), radiological patterns revealed post primary TB in 46%, primary TB in 36%, and miliary TB in 18%. The positivity rates of Ehrlich-Ziehl-Neelsen staining (EZN), polymerase chain reaction (PCR), and TB cultures in clinical samples were found to be 47.5%, 72.5%, and 53%, respectively. Most of our patients (95%) were given the standard TB treatment regimen (HRZE), with a paradoxical reaction observed in 11.6% of cases and hepatotoxicity occurring in 18% of cases. Age, CD4 count (<200 cells/mm3-late presenters), and thrombocytopenia were identified as independent risk factors for mortality in the 58 patients (22%) who died after diagnosis.
Conclusion
Even today, more than one fifth of patients with HIV–TB co-infection in our cohort died. Mortality was higher among individuals who presented late with tuberculosis disease, especially those with advanced immunosuppression (CD4 <200 cells/μL). These findings underscore the urgent need for early HIV diagnosis and systematic TB screening to reduce co-infection–related mortality and improve clinical outcomes.
Citation: Mert A, Derin O, Zerdali E, Kaya A, Gül Ö, Borcak D, et al. (2025) Epidemiological and clinical analysis, and outcomes of tuberculosis co-infection among people living with HIV in Türkiye (2014–2024) ClinSurv HIV cohort: A large case series. PLoS One 20(8): e0329267. https://doi.org/10.1371/journal.pone.0329267
Editor: Zewdu Gashu Dememew, Management Sciences for Health (MSH), ETHIOPIA
Received: September 12, 2024; Accepted: July 14, 2025; Published: August 1, 2025
Copyright: © 2025 Mert et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: Due to privacy and ethical restrictions, data cannot be shared publicly. However, researchers meeting the criteria for access to confidential data may obtain it from the Institutional Ethics Committee (contact: https://sislietfaleah.saglik.gov.tr/TR-604756/etik-kurul.html).
Funding: The author(s) received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Studies of human bones have shown that tuberculosis (TB) is an ancient disease dating back thousands of years, and its cause remained unknown until the discovery of Mycobacterium tuberculosis (M. tuberculosis) by Robert Koch in 1882 [1,2]. Although global incidence is declining, tuberculosis remains a major public health issue, particularly in sub-Saharan Africa. Each year, it affects around 10 million people and causes 1.5 million deaths, making it the leading cause of death from an infectious disease. Even among untreated HIV-negative individuals, pulmonary tuberculosis has a high mortality rate of approximately 50%. However, with the World Health Organization (WHO)’s recommended 6-month anti-TB regimen, about 85% of cases can be successfully cured [3]. Tuberculosis co-infection in people living with HIV (PLHIV) remains a major public health challenge. According to the WHO Global TB Report 2023, an estimated 10.6 million new TB cases occurred in 2022, 7% of which were HIV-positive. Of the 1.3 million TB-related deaths, 13% (167,000) occurred among PLHIV [4]. In 2014, approximately one-quarter of the global population—around 1.7 billion people—was estimated to have tuberculosis infection, previously termed latent tuberculosis infection (LTBI) [5]. The lifetime risk of TB infection progressing to TB disease (previously termed active TB) in immunocompetent individuals is approximately 10% [6]. In PLHIV with TB infection, TB disease develops at approximately 10% (3–21%) per year, with HIV being the most significant risk factor for progression to disease [7]. In patients with TB infection, TB reactivation risk increases with worsening immunodeficiency. Even with effective ART, PLHIV remains at higher TB risk than the general population. While TB was previously the leading infectious cause of death worldwide, HIV remains the most significant risk factor for active TB development.
In our country, while TB incidence has steadily declined (10 cases per 100,000 population in 2020), newly diagnosed HIV cases have surged from 2,687 in 2016–5,710 in 2022. As of 2021, HIV prevalence among TB patients was estimated at 1% [8]. Our review of the English-language medical literature (PubMed) found no large-scale studies on HIV/AIDS-TB co-infection conducted in our country.
This study was the first large-scale investigation of tuberculosis co-infection among PLHIV in Türkiye. We evaluated the clinical characteristics, diagnostic approaches, and outcomes of TB in PLHIV. We assessed co-infection risk, emphasized the importance of early diagnosis and treatment in reducing mortality and transmission, and examined the concurrent use of ART and anti-TB therapy. Given the persistence of high mortality despite the availability of effective treatments, we also explored potential underlying causes.
Methodology
Study design and participants
This study employed a retrospective cohort design to analyze clinical outcomes and survival determinants in people living with HIV (PLHIV) who developed tuberculosis. The analysis was based on a subset of the national ClinSurv HIV cohort, which includes 9,687 PLHIV enrolled across multiple centers in Türkiye. For this study, we included 264 individuals diagnosed and treated for TB between January 2014 and March 2024 at six participating centers. Inclusion criteria required patients to be aged 18 years or older, have confirmed TB, and possess complete medical records available for review.
Case definition
Criteria for TB diagnosis in PLHIV included at least one of the following, alongside strong clinical evidence consistent with active TB — such as current cough [9] or coughing lasting more than two weeks [10,11], fever, night sweats, anorexia, weight loss, fatigue, headache, mental changes, chest pain, lymphadenopathy, or relevant radiological findings: 1) Microbiological criterion, 2) Pathological criterion (histologic evidence of caseating or noncaseating necrotizing granulomas), 3) Pathological criterion + microbiological criterion. Microbiological criterion was established by acid-fast bacilli (AFB) smear, nucleic acid amplification (NAA) testing (GeneXpert MTB/RIF and GeneXpert MTB/RIF Ultra), and isolation of M. tuberculosis from a bodily fluid (e.g., the culture of sputum, bronchoalveolar lavage, or pleural-pericardial-peritoneal fluid) or tissue (e.g., biopsy) [9–11]. The Ehrlich-Ziehl-Neelsen (EZN) method was used to AFB from clinical samples (fluid or solid tissue). M. tuberculosis was cultured in Löwenstein–Jensen (LJ) media and Mycobacterial Growth Indicator Tube (MGIT, Becton Dickinson). M. tuberculosis DNA was investigated by polymerase chain reaction (PCR). The clinical forms of TB were classified according to CDC criteria as follows: pulmonary TB only, extrapulmonary TB (EPTB) only, and combined pulmonary and extrapulmonary TB [12].
Anti-TB drug combinations, their side effects, and complications of the disease were also noted. The diagnosis of hepatotoxicity from anti-TB drugs was established by the presence of at least one of the following: In cases where aminotransferase is five or more times higher than the upper limit of normal (with or without symptoms), or three or more times higher in the presence of symptoms or jaundice (i.e., bilirubin >3 mg/dL) [13].
Patients fulfilling the diagnostic criteria of fever of unknown origin (FUO) and paradoxical reaction were also determined [14,15]. FUO is characterized by a fever higher than 38.3°C on several occasions, persisting without a diagnosis for at least 3 weeks despite at least 1 week of investigation in the hospital. Paradoxical reaction is defined as immune reconstitution inflammatory syndrome (IRIS) after the initiation of antiretroviral therapy (ART) in patients being treated for TB. Paradoxical reaction refers to the transient worsening of a pre-existing tuberculous lesion or the development of new lesions during proper anti-TB therapy.
Data collection
Clinical, demographic, laboratory, microbiological, and radiological data were extracted, including age, sex, ethnicity, TB type (pulmonary or extrapulmonary), HIV status (CD4 count, viral load), and treatment outcomes. Treatment details, including anti-TB and ART types, were collected. The primary outcome was survival status at the end of follow-up. Tuberculin skin tests (TST) and interferon-γ release assays (IGRAs) were recorded. TST induration was measured in millimeters after 48–72 hours by experienced staff, with ≥5 mm considered positive in immunosuppressed patients. Serology results (HBsAg, anti-HCV, syphilis) were also included.
Statistical analysis
Data were analyzed using R statistical software. Descriptive statistics (mean, standard deviation, frequencies, and percentages) were used to summarize the characteristics of the participants. Differences in survival outcomes were evaluated using Chi-squared tests for independence between categorical variables and Wilcoxon rank-sum tests for comparing distributions of continuous variables. Multivariable logistic regression was performed to identify independent predictors of mortality, with results expressed in adjusted odds ratios (aORs) and 95% confidence intervals (CIs). The final model was developed using a stepwise logistic regression approach, considering both forward and backward selection. The fit of the final model was evaluated using the residual deviance and the Akaike Information Criterion (AIC). Missing data were handled using complete case analysis, where only records with no missing values for relevant variables were included in the analysis.
Results
Participant characteristics
Over the past decade, TB occurred in 264 (2.7%) of 9,687 PLHIV under follow-up. Among the 264 patients, 58 (22%) died, while 206 (78%) survived. The median age at TB diagnosis was 40 years (IQR: 32–48), with deceased patients being older than survivors (median ages: 44, IQR: 32–52 vs. 39, IQR: 32–46; p = 0.017). Most patients were male (89%) and of Türkiye origin (91%). Clinical and laboratory characteristics at admission are summarized in Tables 1 and 2.
Lymphadenopathy (LAP) was present in 42% (110), with 70% showing generalized LAP and 30% localized LAP (Table 3). TB clinical forms are shown in Fig 1. Opportunistic infections and malignancies were observed in 23% (n = 62) of HIV/TB co-infected patients and are detailed in Table 4.
Positivity rates for EZN, PCR, and TB cultures in clinical samples were 47.5%, 88%, and 56%, respectively (Table 5). Tissue biopsy granulomas (n = 70) showed necrosis in 71% (50/70) and caseous necrosis in 17% (12/70). HBsAg, anti-HCV, and syphilis serology positivity rates were 9% (24/261), 3% (8/259), and 15% (n = 38/253), respectively.
Clinical and treatment outcomes
Of the TB diagnoses, 51% were pulmonary, 49% extrapulmonary, and 8.7% involved both forms. Miliary TB was more common in deceased patients (29% vs. 16% in survivors; p = 0.017). Deceased patients had a significantly lower median CD4 count at TB diagnosis (55 vs. 100 cells/μL; p = 0.001) and higher HIV viral loads (median: 635,697 vs. 373,366 copies/mL; p = 0.13).
Survivors had a longer median anti-TB treatment duration than those who died (9 vs. 4 months; p < 0.001). Among 242 patients with available ART regimen data, the most common regimen was dolutegravir plus tenofovir disoproxil fumarate/emtricitabine (DTG + TDF/FTC), used in 53.7% of cases. Efavirenz-based regimens (EFV + TDF/FTC) and lopinavir/ritonavir + TDF/FTC were used in 23.6% and 10.3% of patients, respectively. Among 202 patients with known ART timing, the median interval from anti-TB treatment initiation to ART initiation was 3 weeks (IQR: 2–5), and 13 patients (6.4%) were already on ART at the time of TB diagnosis. ART timing did not differ significantly between deceased and surviving patients (2.5 vs. 3 weeks; p = 0.5). Among patients with TB meningitis (n = 29), ART was initiated at a median of 4.5 weeks (IQR: 3–9), compared to 3.0 weeks (IQR: 2–5.5) in those without meningitis, with no statistically significant difference (p = 0.239).
Predictors of mortality
The univariable and multivariable analyses of factors associated with mortality in HIV/TB co-infected patients are summarized in Table 6. Univariable analysis identified several significant mortality risk factors, including older age (OR: 1.04, 95% CI: 1.01, 1.07), fever (OR: 3.43, 95% CI: 1.57,8.66), dyspnea (OR: 2.46, 95% CI: 1.26, 4.75), altered consciousness (OR: 2.76, 95% CI: 1.34, 5.59), weight loss (OR: 2.93, 95% CI: 1.27, 7.96), disseminated LAP (OR: 3.93, 95% CI: 1.21,17.7), and CD4 count <200 cells/mm3 (OR: 2.79, 95% CI: 1.31,6.69). Thrombocytopenia (OR: 2.48, 95% CI: 1.31, 4.67) and pancytopenia (OR: 3.29, 95% CI: 1.54, 6.94) were also associated with increased mortality.
Multivariable analysis confirmed older age (OR: 1.05, 95% CI: 1.02, 1.09), thrombocytopenia (OR: 2.54, 95% CI: 1.10,5.90), and low CD4 count, especially with non-homosexual transmission routes (OR: 15.6, 95% CI: 1.85,186), as independent mortality predictors.
The interaction between CD4 count and transmission route highlighted the increased effect of immune suppression in non-homosexual transmission. In our analysis of mortality factors in HIV/TB co-infected patients, significant differences in clinical and demographic variables were noted across transmission routes (Table 6). A CD4 count <200 cells/mm3 had an OR of 2.79 for mortality in univariable analysis, which shifted to 0.18 in multivariable analysis, prompting further investigation of interactions with other variables, particularly HIV transmission routes. The interaction analysis revealed that a CD4 count <200 cells/mm3 in non-homosexual transmission routes was associated with a markedly higher OR of 15.6 for mortality. The non-homosexual group had older median age and more severe inflammatory markers at diagnosis. Median age of deceased patients was 46 years (IQR: 33–54) in the non-homosexual group versus 37 years (IQR: 31–50) in the homosexual group, suggesting age as a contributing factor to higher mortality. Details of the multivariable model and interaction terms are provided in supporting file (S1 File).
Inflammatory markers were also elevated in the non-homosexual group, with median CRP levels of 85 mg/L compared to 29 mg/L in the homosexual group and median ESR of 90 mm/h versus 67 mm/h.
Discussion
In this study, TB developed in 3% of PLHIV, with 90% of cases being male. Half had extrapulmonary TB, and lymphadenopathy was present in 50%, two-thirds of whom had systemic lymphadenitis. Post-primary pulmonary TB was the most common presentation, identified in about half of the patients, followed by primary TB in nearly a third, and miliary TB in approximately one-fifth. EZN and TB culture positivity were observed in half of the samples, while PCR was positive in 75%. Nearly all patients received the standard TB regimen, with paradoxical reactions in 10% and hepatotoxicity in 20%. Age, CD4 lymphopenia, and thrombocytopenia were risk factors for mortality, which occurred in 20% of cases.
Opportunistic infections (OIs) are common and a leading cause of death in advanced HIV/AIDS patients. TB, prevalent in all stages of HIV infection, is a frequent OI. A southern China study of hospitalized HIV patients (60% with AIDS) found 71% (n = 8,982/12,612) developed OIs, with TB in 35% [16]. A Turkish systematic review showed a 17% OI rate in PLHIV, with TB at 5.5% [17]. This HIV cohort study found TB in 2.7% of PLHIV, with OIs in roughly 25% of HIV/AIDS-TB co-infections. These findings highlight the persistent burden of TB as an OI in PLHIV, emphasizing the need for early detection and comprehensive management strategies.
Before 2010, TB diagnosis primarily relied on EZN staining and cultures, which had limitations: low sensitivity for AFB smears and slow results for cultures. FDA-approved NAA tests (Xpert MTB/RIF in 2010 and Xpert MTB/RIF Ultra in 2017) reduced diagnosis time and rifampicin resistance determination to 2 hours, leading to WHO recommendations for their use [18,19]. Sputum AFB microscopy has low sensitivity (62%) but high specificity (100%) [20]. Xpert MTB/RIF and Ultra show higher sputum sensitivity (75% and 88%) and specificity (100% and 93%) [21]. However, sensitivity varies for extrapulmonary TB (EPTB) due to lower bacillus loads in fluid/tissue samples. A meta-analysis found EPTB sensitivity for Xpert MTB/RIF or Ultra at 50–90% and specificity >90% [22]. In this study, PCR testing of 101 diverse clinical samples, including sputum, fluid, and tissue specimens, demonstrated an 88% positivity rate for the M. tuberculosis complex. These findings highlight the ongoing need for advanced molecular diagnostics, particularly for EPTB, where traditional methods remain less effective.
TSTs and IGRAs, reflecting adaptive immune responses to mycobacterial antigens, indicate TB exposure but don’t diagnose active disease. Test negativity (anergy) is more likely with lower CD4 counts [23]. Of 87 patients tested (66 TST, 21 IGRA), the combined positivity rate was 55% (n = 48). Positivity was 44% (n = 28) in those with CD4 counts <200 and 83% (n = 20) in those with CD4 counts ≥200.
In the USA in 2022, most TB cases were PTB only (70.4%), followed by EPTB only (18.8%), and both (10.6%) [12]. Of the 8925 TB cases reported in Türkiye in 2020, 65% (n = 5802) were PTB, and 35% (n = 3123) were EPTB [8]. Lower CD4 counts (<200) in AIDS patients increase the likelihood of both PTB and EPTB [23]. Studies on HIV/AIDS-TB co-infection show this co-occurrence ranging from 28% to 90% [24–27]. In this study, we found 42.4% PTB only, 48.8% EPTB only, and 8.7% both. This lower co-occurrence rate compared to other studies may be due to the retrospective and heterogeneous nature of these studies, leading to varied distribution rates.
HIV infection alters PTB radiographic patterns based on immunodeficiency severity. Patients with CD4 ≥ 200 cells/mm3 typically present with upper lobe consolidation and cavitation, resembling TB in HIV-negative individuals, where post-primary PTB primarily affects the apical-posterior segment of the upper lobes, followed by the superior segment of the lower lobes and the anterior segment of the upper lobes [22,28]. Common findings include consolidation, often with cavitation, but without hilar or mediastinal adenopathy. Conversely, in AIDS patients, post-primary PTB often mimics primary TB radiographically, showing atypical patterns. These include middle or lower lung involvement, non-cavitating nodular opacities or consolidation, pleural effusions, and often hilar/mediastinal adenopathy. Upper lobe consolidation or cavitation is less common. In some cases, chest X-rays may even appear normal. Frey et al. found that adults with low CD4 counts (<200 cells/µL) are more frequently presented with mediastinal lymphadenopathy and miliary patterns, while cavitation and consolidation were less likely [29]. Greenberg et al. observed a range of radiographic presentations in AIDS patients with PTB, including primary TB patterns (36%), post-primary patterns (28%), atypical infiltrates (13%), minimal changes (5%), miliary patterns (3%), and normal radiographs (15%) [30]. Notably, about 15% of AIDS patients with confirmed PTB have negative chest X-rays, a rarity in non-AIDS patients [31,32]. Chest CT scans of 200 patients in this study revealed diverse radiological patterns. This study aligns with previous research, showing post-primary PTB in 46%, primary TB in 36%, and miliary TB in 18%. Lower CD4 counts (≤200) were associated with a higher prevalence of primary (39% vs 27%) and miliary TB (19% vs 16%). Given these variations, non-contrast chest CT is a valuable tool in detecting TB in PLHIV.
TB lymphadenitis (LAP) is the most frequent form of EPTB [23]. While typically affecting the cervical lymph nodes (often unilaterally), it can also occur in axillary, inguinal, and supraclavicular regions [32–34]. Clinical manifestations vary depending on the location and the patient’s immune status. In AIDS patients, TB LAP often involves a significant mycobacterial load, leading to systemic symptoms like fever, sweating, and weight loss. Generalized TB LAP (70%) is more common in AIDS patients, compared to 17%−35% in immunocompetent individuals, as seen in this study.
The standard treatment consists of isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E). The standard treatment for pulmonary or extrapulmonary TB with susceptible pathogens is (2HRZE/4HR), lasting ≥6 months, regardless of age, disease severity, or HIV status [13]. The treatment regimen or duration, including induction and continuation phases, may be adjusted based on the site of involvement and drug resistance. However, recovery in HIV/AIDS-TB co-infection is challenging due to immunosuppression and treatment non-compliance [35,36]. Therefore, HIV screening is recommended for all TB patients, as HIV and TB co-infection are common, and HIV co-infection influences TB’s course and treatment. In 2022, the WHO recommended a 6-month bedaquiline, pretomanid, linezolid, and moxifloxacin regimen for most rifampin-resistant TB cases, including those with HIV [37]. While steroids are recommended for HIV-associated TB meningitis, they may not improve mortality or neurological outcomes [38]. Early ART initiation is crucial in HIV-TB co-infection to reduce HIV-related morbidity and mortality. The WHO recommends starting ART within 2 weeks of TB treatment, irrespective of CD4 count, except for TB meningitis cases, where a 4–8-week delay is advised [9]. Early ART initiation lowers mortality but may increase IRIS risk, especially with CD4 counts below 50 [39]. In this study, 95% (252/264) of patients received the standard HRZE regimen. Rifabutin was used instead of rifampin in five cases, while four cases required the addition of moxifloxacin. One patient with choroidal tubercles and visual impairment replaced ethambutol with moxifloxacin. Eight cases received MDR-TB treatment, and one patient died before treatment initiation.
Hepatotoxicity, a potential side effect of isoniazid, rifampin, or pyrazinamide, occurs in 8% to 28% of HIV/AIDS-TB patients undergoing treatment [40]. In this study, 18% (47/264) of patients developed hepatotoxicity, consistent with published data. Close monitoring of liver function tests and timely regimen adjustments are essential to minimize treatment interruptions and improve adherence.
In line with the EACS 2024 guidelines [41], ART should be initiated in all individuals with TB/HIV co-infection regardless of CD4 count, with earlier initiation (within 2 weeks) recommended for those with CD4 < 50 cells/µL, except in cases of TB meningitis where ART should be delayed by 4 weeks. In this cohort, the median ART initiation time was 3 weeks, and approximately 6% of patients were already on ART at the time of TB diagnosis. No significant difference was observed in ART timing between patients who died and those who survived, suggesting that ART initiation may have been appropriately individualized based on clinical presentation. Among patients with TB meningitis, the median ART initiation was slightly delayed (4.5 weeks vs. 3.0 weeks), though this difference was not statistically significant, possibly reflecting clinical caution due to IRIS risk. The most frequently used ART regimen was dolutegravir combined with TDF/FTC, consistent with guideline-based recommendations.
A meta-analysis found an 18% incidence of paradoxical TB-associated IRIS in HIV-TB patients starting ART [41]. Higher IRIS rates are linked to lower CD4 counts, high HIV viral loads at ART initiation, and shorter intervals between TB treatment and ART initiation. IRIS typically occurs within 60 days of starting ART, though the range varies from 10 to 180 days [15]. In this study, 11.6% (n = 29/250) of patients developed TB-IRIS, typically at a median of 4 weeks (IQR: 3.3 to 8.0) after starting TB treatment. Importantly, IRIS development did not increase mortality in the patients in this study.
An estimated 39 million people were living with HIV at the end of 2022, with 1.3 million new infections and 630,000 AIDS-related deaths globally [42]. TB is a leading cause of death in people co-infected with HIV and TB. Autopsy studies in high TB-burden African countries show TB, particularly disseminated TB, as the most common cause of death (69%−79%) in AIDS patients [43–46]. Mortality rates in HIV-TB co-infected patients during treatment range from 5% to 37.6% [47–54]. In a South African study, the incidence of TB was still four times higher among individuals with normalized CD4 counts on ART compared to those living in the same community who did not have HIV infection [55]. TB meningitis in HIV-infected individuals carries a high mortality rate, around 40% [56]. The mortality rate in this study was 22%, which is consistent with rates reported in similar studies [48–55]. In this study, surviving patients received a median of 9 months of anti-TB treatment, whereas those who died had received a median of 4 months at the time of death.
Several studies have identified key risk factors associated with increased mortality among patients with HIV/TB co-infection, including advanced age, tuberculous meningitis, hypoalbuminemia, anemia, low CD4 cell count, disseminated TB, absence of antiretroviral therapy (ART), and coexisting non-AIDS-related comorbidities [47–53]. The multivariable logistic regression analysis identified older age, low CD4 count (<200 cells/mm3), and thrombocytopenia as independent predictors of mortality. Notably, a significant interaction was observed between HIV transmission route and CD4 count, underscoring the role of late HIV diagnosis in adverse outcomes. This finding is consistent with previous studies suggesting that individuals infected through heterosexual transmission are more likely to present with advanced immunosuppression due to delayed diagnosis [57]. This is further supported by the elevated inflammatory markers (ESR and CRP) observed in the non-homosexual group, indicating more severe disease at presentation. These findings are consistent with the interaction effect identified in our analysis, wherein non-homosexual transmission routes were associated with a significantly increased risk of mortality, particularly in the context of advanced immunosuppression.
The combination of older age, elevated inflammatory markers, and severe immunosuppression among non-homosexual individuals underscores the need for targeted interventions. Efforts to reduce delays in HIV diagnosis and improve early engagement in care—particularly in heterosexual populations—may significantly improve clinical outcomes and reduce mortality in this vulnerable group.
This study highlights the critical importance of early diagnosis and timely treatment in improving outcomes and preventing TB transmission among PLHIV. Despite the availability of effective ART and anti-TB therapies, persistently high mortality rates point to delays in diagnosis. To mitigate this, the use of non-contrast thoracic CT imaging at initial assessment—particularly in asymptomatic individuals with normal lung exams but elevated inflammatory markers (CRP and/or ESR)—may aid in earlier TB detection. Furthermore, prophylactic treatment for individuals with latent TB infection remains essential in reducing progression to active disease.
This study has several strengths. First, the analysis was based on a subset of the national ClinSurv HIV cohort, which includes 9,687 people living with HIV (PLHIV) enrolled across multiple centers in Türkiye. From this cohort, we included 264 individuals diagnosed and treated for tuberculosis between January 2014 and March 2024—constituting one of the largest case series on TB co-infection among PLHIV in the country. Second, the multi-center design, with data collected from six geographically diverse centers, enhances the generalizability of the findings and reduces the potential for single-center bias. Third, the study incorporated a wide range of clinical, demographic, laboratory, microbiological, and radiological variables, allowing for a comprehensive and in-depth analysis of TB co-infection in PLHIV.
This study has several limitations. First, its retrospective design limits the ability to establish causal relationships between variables. Second, the analysis relies on the availability and completeness of medical records, which may introduce information bias. Third, as the study was conducted solely in Türkiye, the findings may not be fully generalizable to other settings with different epidemiological patterns or healthcare systems. Lastly, data on isoniazid preventive therapy (IPT) use were unavailable, as this information was not systematically collected across study sites, limiting the ability to evaluate the protective role of IPT against TB progression in this population.
In conclusion, even today, 22% of our patients with HIV-TB co-infection have died. Mortality is higher among those with AIDS-TB co-infection. Diagnosing HIV-infected patients before they progress to the AIDS stage and initiating ART appears to be among the most important strategies for preventing deaths from TB.
Supporting information
S1 File. Supporting material for logistic regression model development.
https://doi.org/10.1371/journal.pone.0329267.s001
(PDF)
References
- 1. Hershkovitz I, Donoghue HD, Minnikin DE, May H, Lee OY-C, Feldman M, et al. Tuberculosis origin: the Neolithic scenario. Tuberculosis (Edinb). 2015;95(Suppl 1):S122-6. pmid:25726364
- 2. Sakula A. Robert koch: centenary of the discovery of the tubercle bacillus, 1882. Can Vet J. 1983;24(4):127–31. pmid:17422248
- 3. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJD. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One. 2011;6(4):e17601. pmid:21483732
- 4.
World Health Organization. Tuberculosis fact sheet. 2023.
- 5. Houben RMGJ, Dodd PJ. The Global Burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152. pmid:27780211
- 6. Comstock GW. Epidemiology of tuberculosis. Am Rev Respir Dis. 1982;125(3 Pt 2):8–15. pmid:7073104
- 7. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;2010(1):CD000171. pmid:20091503
- 8.
Türkiye’de verem savaşı 2021 raporu. 1274. Sağlık Bakanlığı. 2023. https://hsgm.saglik.gov.tr/depo/birimler/tuberkuloz-db/Dokumanlar/Raporlar/Turkiyede_Verem_Savasi_2021_Raporu.pdf#page=3.73
- 9.
World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery, and monitoring: recommendations for a public health approach. 2021.
- 10. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64(2):111–5. pmid:28052967
- 11.
Case definitions - Treatment of Tuberculosis: Guidelines. [Accessed 2025 February 8]. https://www.ncbi.nlm.nih.gov/books/NBK138741/
- 12.
Centers for Disease Control P. Reported Tuberculosis in the United States, 2022. 2023. https://www.cdc.gov/tb-surveillance-report-2023/summary/national.html#:~:text=In%202023%2C%20the%20United%20States,to%20the%20COVID%2D19%20pandemic.
- 13.
World Health Organization. WHO consolidated guidelines on tuberculosis, module 4: treatment - drug-susceptible tuberculosis treatment. 2022.
- 14. Petersdorf RG, Beeson PB. Fever of unexplained origin: report on 100 cases. Medicine (Baltimore). 1961;40:1–30. pmid:13734791
- 15. Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore). 2002;81(3):213–27. pmid:11997718
- 16. Meng S, Tang Q, Xie Z, Wu N, Qin Y, Chen R, et al. Spectrum and mortality of opportunistic infections among HIV/AIDS patients in southwestern China. Eur J Clin Microbiol Infect Dis. 2023;42(1):113–20. pmid:36413338
- 17. Önal U, Akalın H. Opportunistic infections among Human Immunodeficiency Virus (HIV) infected patients in turkey: a systematic review. Infect Dis Clin Microbiol. 2023;5(2):82–93. pmid:38633009
- 18. Shen Y, Yu G, Zhong F, Kong X. Diagnostic accuracy of the Xpert MTB/RIF assay for bone and joint tuberculosis: a meta-analysis. PLoS One. 2019;14(8):e0221427. pmid:31437232
- 19. Zhang M, Xue M, He J-Q. Diagnostic accuracy of the new Xpert MTB/RIF Ultra for tuberculosis disease: a preliminary systematic review and meta-analysis. Int J Infect Dis. 2020;90:35–45. pmid:31546008
- 20. Matee M, Mtei L, Lounasvaara T, Wieland-Alter W, Waddell R, Lyimo J, et al. Sputum microscopy for the diagnosis of HIV-associated pulmonary tuberculosis in Tanzania. BMC Public Health. 2008;8:68. pmid:18289392
- 21. Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG, et al. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. Cochrane Database Syst Rev. 2021;2(2):CD009593. pmid:33616229
- 22. Kohli M, Schiller I, Dendukuri N, Yao M, Dheda K, Denkinger CM, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2021;1(1):CD012768. pmid:33448348
- 23. Meintjes G, Maartens G. HIV-Associated tuberculosis. N Engl J Med. 2024;391(4):343–55. pmid:39047241
- 24. Shivakoti R, Sharma D, Mamoon G, Pham K. Association of HIV infection with extrapulmonary tuberculosis: a systematic review. Infection. 2017;45(1):11–21. pmid:27830524
- 25. Sunderam G, McDonald RJ, Maniatis T, Oleske J, Kapila R, Reichman LB. Tuberculosis as a manifestation of the acquired immunodeficiency syndrome (AIDS). JAMA. 1986;256(3):362–6. pmid:3723722
- 26. Modilevsky T, Sattler FR, Barnes PF. Mycobacterial disease in patients with human immunodeficiency virus infection. Arch Intern Med. 1989;149(10):2201–5. http://www.ncbi.nlm.nih.gov/pubmed/2802887 pmid:2802887
- 27. Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis. 1993;148(5):1292–7. pmid:7902049
- 28. Lau A, Barrie J, Winter C, Elamy A-H, Tyrrell G, Long R. Chest radiographic patterns and the transmission of tuberculosis: implications for automated systems. PLoS One. 2016;11(4):e0154032. pmid:27105337
- 29. Frey V, Phi Van VD, Fehr JS, Ledergerber B, Sekaggya-Wiltshire C, Castelnuovo B, et al. Prospective evaluation of radiographic manifestations of tuberculosis in relationship with CD4 count in patients with HIV/AIDS. Medicine (Baltimore). 2023;102(7):e32917. pmid:36800631
- 30. Greenberg SD, Frager D, Suster B, Walker S, Stavropoulos C, Rothpearl A. Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance). Radiology. 1994;193(1):115–9. pmid:7916467
- 31. McGuinness G, Gruden JF, Bhalla M, Harkin TJ, Jagirdar JS, Naidich DP. AIDS-related airway disease. AJR Am J Roentgenol. 1997;168(1):67–77. pmid:8976923
- 32. Geldmacher H, Taube C, Kroeger C, Magnussen H, Kirsten DK. Assessment of lymph node tuberculosis in northern Germany: a clinical review. Chest. 2002;121(4):1177–82. pmid:11948050
- 33. Yenilmez E, Özakınsel D, Köse A, Olçar Y, Duman Z, Ceylan MR, et al. Diagnostic approach of tuberculous lymphadenitis in a multicenter study. J Infect Dev Ctries. 2024;18(5):742–50. pmid:38865395
- 34. Mert A, Tabak F, Ozaras R, Tahan V, Oztürk R, Aktuğlu Y. Tuberculous lymphadenopathy in adults: a review of 35 cases. Acta Chir Belg. 2002;102(2):118–21. pmid:12051084
- 35. Tanue EA, Nsagha DS, Njamen TN, Assob NJC. Tuberculosis treatment outcome and its associated factors among people living with HIV and AIDS in Fako Division of Cameroon. PLoS One. 2019;14(7):e0218800. pmid:31361755
- 36. Zhang Y, Sun K, Yu L, Tang Z, Huang S, Meng Z, et al. Factors associated with survival among adults with HIV-Associated TB in Guangxi, China: a retrospective cohort study. Future Virol. 2012;7(9):933–42.
- 37.
World Health Organization. WHO consolidated guidelines on tuberculosis, module 4: treatment - drug-resistant tuberculosis treatment. 2022 update. Pan American Health Organization; 2022. https://www.paho.org/en/documents/who-consolidated-guidelines-tuberculosis-module-4-treatment-drug-resistant-tuberculosis
- 38. Donovan J, Bang ND, Imran D, Nghia HDT, Burhan E, Huong DTT, et al. Adjunctive dexamethasone for tuberculous meningitis in HIV-positive adults. N Engl J Med. 2023;389(15):1357–67. pmid:37819954
- 39. Uthman OA, Okwundu C, Gbenga K, Volmink J, Dowdy D, Zumla A, et al. Optimal timing of antiretroviral therapy initiation for HIV-Infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis. Ann Intern Med. 2015;163(1):32–9. pmid:26148280
- 40. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–52. pmid:17021358
- 41. Namale PE, Abdullahi LH, Fine S, Kamkuemah M, Wilkinson RJ, Meintjes G. Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis. Future Microbiol. 2015;10(6):1077–99. pmid:26059627
- 42.
World Health Organization WHO. Global HIV Programme, HIV Data and Statistics. [Accessed 2025 February 8]. https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics
- 43. Martinson NA, Karstaedt A, Venter WDF, Omar T, King P, Mbengo T, et al. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS. 2007;21(15):2043–50. pmid:17885294
- 44. Wong EB, Omar T, Setlhako GJ, Osih R, Feldman C, Murdoch DM, et al. Causes of death on antiretroviral therapy: a post-mortem study from South Africa. PLoS One. 2012;7(10):e47542. pmid:23094059
- 45. Bates M, Mudenda V, Mwaba P, Zumla A. Deaths due to respiratory tract infections in Africa: a review of autopsy studies. Curr Opin Pulm Med. 2013;19(3):229–37. pmid:23429099
- 46. Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ, et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV. 2015;2(10):e438-44. pmid:26423651
- 47. Zhang Z, Xu L, Pang X, Zeng Y, Hao Y, Wang Y, et al. A Clinical scoring model to predict mortality in HIV/TB co-infected patients at end stage of AIDS in China: an observational cohort study. Biosci Trends. 2019;13(2):136–44. pmid:30930360
- 48. Teixeira F, Raboni SM, Ribeiro CE, França JC, Broska AC, Souza NL. Human immunodeficiency virus and tuberculosis coinfection in a tertiary hospital in Southern Brazil: Clinical profile and outcomes. Microbiol Insights. 2018;11:1178636118813367. pmid:30505151
- 49. Gatechompol S, Kawkitinarong K, Suwanpimolkul G, Kateruttanakul P, Manosuthi W, Sophonphan J, et al. Treatment outcomes and factors associated with mortality among individuals with both TB and HIV in the antiretroviral era in Thailand. J Virus Erad. 2019;5(4):225–30. pmid:31754446
- 50. Pepper DJ, Schomaker M, Wilkinson RJ, de Azevedo V, Maartens G. Independent predictors of tuberculosis mortality in a high HIV prevalence setting: a retrospective cohort study. AIDS Res Ther. 2015;12:35. pmid:26448780
- 51. Pecego AC, Amancio RT, Ribeiro C, Mesquita EC, Medeiros DM, Cerbino J, et al. Six-month survival of critically ill patients with HIV-related disease and tuberculosis: a retrospective study. BMC Infect Dis. 2016;16:270. pmid:27286652
- 52. Bigna JJR, Noubiap JJN, Agbor AA, Plottel CS, Billong SC, Ayong APR, et al. Early mortality during initial treatment of tuberculosis in patients co-infected with HIV at the Yaoundé Central Hospital, Cameroon: an 8-year retrospective cohort study (2006-2013). PLoS One. 2015;10(7):e0132394. pmid:26214516
- 53. de Resende NH, de Miranda SS, Reis AMM, de Pádua CAM, Haddad JPA, da Silva PVR, et al. Factors associated with the effectiveness of regimens for the treatment of tuberculosis in patients coinfected with HIV/AIDS: cohort 2015 to 2019. Diagnostics (Basel). 2023;13(6):1181. pmid:36980489
- 54. Lamprecht DJ, Martinson N, Variava E. Effect of HIV on mortality among hospitalised patients in South Africa. South Afr J HIV Med. 2023;24(1):1477. pmid:37153012
- 55. Gupta A, Wood R, Kaplan R, Bekker L-G, Lawn SD. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One. 2012;7(3):e34156. pmid:22479548
- 56. Wilkinson RJ, Rohlwink U, Misra UK, van Crevel R, Mai NTH, Dooley KE, et al. Tuberculous meningitis. Nat Rev Neurol. 2017;13(10):581–98. pmid:28884751
- 57. Sevgi DY, Demirbas ND, Genc Yaman I, Derin O, Oncul A, Atasoy Tahtasakal C, et al. Evaluation of the late presentation and associated factors of people living with HIV in Turkey. J Med Virol. 2023;95(5):e28781. pmid:37212337